Stockreport

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

Cardiff Oncology, Inc.  (CRDF) 
PDF SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel [Read more]